Protagenic Completes First Dosing in PT00114 Phase 1 Multiple-Dose Study

Protagenic Therapeutics said on Thursday it has finished administering the first dose to all participants in the multiple-dose portion of its ongoing Phase 1 study of PT00114, a synthetic peptide aimed at treating stress- and mood-related disorders including anxiety, depression and post-traumatic stress disorder. The New York-based company expects to complete the remaining dosing regimen by the end of August and to report top-line safety results by late September. Positive data would allow Protagenic to move the candidate into a Phase 2 efficacy trial targeted for the first quarter of 2026. PT00114 is the first therapy derived from Teneurin C-terminus Associated Peptide, a brain hormone that modulates stress responses. The experimental drug’s mechanism differs from existing treatments that primarily suppress symptoms, potentially offering a new approach for patients who do not respond adequately to current therapies. Investors welcomed the milestone: Protagenic shares jumped about 69 percent in pre-market trading, trading near $2.28, after the announcement.